Annovis Bio, Inc. (ANVS)
CIK 1477845 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 34.6M shares as of May 15, 2026 (10-Q).
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Think Equity Warrants Expiration February42030 | 5.3M | $5 | — | — |
| Warrants Classified As Liabilities Expiration November22028 | 308,333 | $9 | — | — |
| Warrants Classified As Liabilities | 308,333 | $9 | 5y | — |
| Placement Agent Warrants Expiration October142030 | 200,000 | $2.2 | — | — |
| Placement Agent Warrants Expiration October202030 | 83,537 | $2.56 | — | — |
| Placement Agent Warrants | 83,357 | $2.56 | 5y | FV $100,000 |
| Warrants Classified As Equity | not tagged | $7.5 | 5y | — |
| Think Equity Warrants | not tagged | $5 | 5y | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 15, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 2,400 underlying shares, as reported Sep 30, 2023 (10-Q).
Rough fully diluted estimate: 34.6M = 34.6M O/S + 2,400 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed May 15, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 34.6M | May 15, 2026 |
| + Think Equity Warrants Expiration February42030 (if exercised) | 5.3M | Mar 31, 2026 |
| + Warrants Classified As Liabilities Expiration November22028 (if exercised) | 308,333 | Mar 31, 2026 |
| + Warrants Classified As Liabilities (if exercised) | 308,333 | Mar 31, 2026 |
| + Placement Agent Warrants Expiration October142030 (if exercised) | 200,000 | Mar 31, 2026 |
| + Placement Agent Warrants Expiration October202030 (if exercised) | 83,537 | Mar 31, 2026 |
| + Placement Agent Warrants (if exercised) | 83,357 | Oct 26, 2025 |
| Fully diluted estimate | 40.9M | +18.0% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 5 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ANVS workspace